The latest call
FetchingGeron Corp. reported on 2026年11月4日. We are fetching the call transcript; its summary follows once the transcript is in.
US$0.97-2.7%11月13日 收盘
数据截至2026年9月30日,来自2026年11月4日提交的10-Q
Just reported
From Geron Corp.'s results release of 2026年11月4日; its quarterly report has since been filed.
Actual
US$60.2M
+27% y/y
+4.7% q/q
Guided
—
No guide given
Actual
US$0.00
Guided
—
No guide given
Actual
US$5.8M
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年6月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$60.2M | US$49M | +22.75% |
| 利润 | US$1.4M | -US$18.4M | +107.33% |
| 每股收益 | US$0.00 | -US$0.03 | +100.00% |
这些是单季度数字,不是滚动一年——本站其他地方的数字覆盖十二个月,会大得多。季节性业务在两者之间摆动很大:ServiceNow 在十二月季度赚 20 亿美元自由现金流,在六月季度只有 5 亿。
对比对象是去年同一季度,而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据,那是我们没有的授权数据——而搞错它比不提更糟。
Geron Corp. reported on 2026年11月4日. We are fetching the call transcript; its summary follows once the transcript is in.
“Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.,”
逐字引自公告,且只在文件将其归于具名人士时才展示。
公告在开盘前或收盘后发布,因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况,反应都包含在内。
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO ® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn. Use of
公司自己的描述,取自公告末尾。
引述和公司简介来自 Geron Corp. 于 2026年11月4日 提交的第 2.02 项 8-K 文件;表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.